Managing Autism. Neuroscience steps in to Help.
After over six years of research, development and extensive user-testing, a cutting-edge neuroscience product designed to help manage the challenging symptoms of autism has just been launched.
The device, MenteTM, which is widely heralded as a first in its field worldwide, is based on Neurofeedback and is specifically developed for home use by autistic children without the need for specialist assistance. It is one of several neuroscience products aimed at the health and medical sector being developed by Malta-based neuroscience research and development lab, AAT Research.
MenteTM itself is closely associated with AAT Founder and Managing Director, neuroscientist Dr Adrian Attard Trevisan, who developed the product after experiencing the challenges a friend faced in managing his son’s condition. The device is set to revolutionise the way parents and health professionals support autism spectrum disorder (ASD) children.
“This is personal for me,” said Dr Adrian Attard Trevisan. “When I was a student in Brittany I stayed with a family whose son had Asperger’s. I spent time observing him, trying to understand his behaviour. I wasn’t observing him dispassionately, as a scientist conducting an experiment. I was watching him carefully to see where and how I could help the boy and my friend. I knew I had to help. This is when I started to think through how Neurofeedback could be key to allowing my friend’s son, and others like him, focus and better engage with the world around them.” While MenteTM works on all ages and across a spectrum of autism conditions, AAT prioritises targeting MenteTM at school-age, autistic children.
Patented Hi-Tech in Action.
In autistic children, the Delta brainwaves, which are naturally elevated at night, remain over-active during the daytime. This causes many of the symptoms and distractions typically associated with autistic people as they struggle to cut through their ‘mental noise’. MenteTM patented technology listens to the autistic child’s brainwaves to create personalised sounds (binaural beats) designed to stimulate the reduction in the user’s Delta brainwaves.
“The technology may be high-tech but the objective is very simple: reduce the user’s Delta wave and the mind becomes calmer,” explains Dr Trevisan. “The idea is not too dissimilar to the way noise- cancelling headphones work. These produce counter-noise to reduce unwanted background sounds. MenteTM does something similar with brainwaves. Luckily, unlike noise-cancelling headphones, the effect of the use of MenteTM lasts even when the MenteTM headband is removed.
For over a decade, neurofeedback technology has proved an effective treatment but has until now only been available in some specialised institutions. MenteTM solves the challenge of making neurofeedback technology available for home use at an affordable price and without the need of
The MenteTM system consists of two components: a headband and software downloaded to the user’s personal computer or smartphone. The headband has five (4 channel) very sensitive EEG pads that pick up minute brainwaves (Alpha, Beta, Delta and Theta waves), emitted by the brain in real time.
The MenteTM software interprets the waves, processes them in real time and converts them into harmless, personalised binaural beats which sound like music and which the user listens to either via the computer’s own speakers or the included headphones.
The software, which can be downloaded to a range of devices (PC, Smartphone, Tablet) communicates with the headband via a Wi-Fi connection and allows the user to go about their daily activities without interruption. A child can continue with most routine activities so long as sound and noise interference are eliminated or kept to a minimum.
Forty minutes a day at home is all it takes.
“All it takes is 40 minute every morning,” says Dr Trevisan. “After that, the effects last the rest of the day until the child goes back to sleep. With sleep, the waves naturally elevate and the process must be repeated the next morning.”
After each session, the software issues a daily report which shows an EEG representation of the key brainwaves before and after each session. This report is designed for easy interpretation and provides a record of the progress the child is making from daily use of the therapy. Uploaded securelyto the cloud, the report is available anytime and anywhere.
“No one treatment will work for everyone, of course” said Dr Attard Trevisan, “but we believe it will work for most children. It takes up to four weeks of daily use for positive results to start appearing.“ Dr Attard Trevisan stresses that MenteTM is not a cure for autism but that it is a highly effective and revolutionary aid in the management of autism. “Parents have told me how well it has worked for their children and transformed their lives and that makes all the sacrifices worthwhile. Their behavioural ￼problems decrease, teachers attest their school performance improves, and carers get some respite from the constant challenge of providing intensive supervision.“
- ENDS -
Notes to Editors:
MenteTM is an FDA Class 2, CE (pending) and ISO 13485-certified (pending) EEG device.
Dr.Attard Trevisan holds a Ph.D in Neuroscience from the University of London and Masters Level qualifications in Engineering and Audiological Sciences from the University of London. He is working on a second Ph.D in Human Physiology at the University of Milan.
Since founding AAT Research his academic partners have been University of Milan and University of Malta. In September 2013, he published a paper describing a clinical trial for the science behind Mente 2 in the Journal of Neurological Disorders, published by the University of California, Irvine. Dr. Attard Trevisan leads a team of six scientists.
[email protected] www.aatresearch.org
￼Tel. +356-2133-0588 AAT Research Ltd.
Marsa Industrial Estate Marsa MRS3000
Press release distributed by Pressat on behalf of AAT Research Ltd , on Thursday 15 May, 2014. For more information subscribe and follow http://www.pressat.co.uk/
Home Based Therapy
Autism Spectrum Disorder
Medical & Pharmaceutical